C D8
+ T cells (T CD8+ ) are a critical component of the adaptive immune response against viral infections. These cells recognize complexes of peptides and MHC class I (pMHC-I) molecules on the surface of APCs. In theory, following viral infection, T CD8+ can recognize a vast range of presented viral peptides. However, for any given virus, T CD8+ responses are, in reality, directed toward only a limited number of pMHC-I. This phenomenon, referred to as "immunodominance" (ID), is further characterized by a hierarchy of immunodominant determinants that reproducibly elicit the largest T CD8+ response and of subdominant determinants that induce relatively smaller responses (1) .
Elucidating the mechanisms that contribute to ID is critical to the future development of effective T CD8+ -based vaccines. Numerous factors that contribute to ID have been identified. On the one hand, multiple factors directly related to the Ag appear to be important, including the efficiency of Ag processing and presentation (2) (3) (4) , the stability of pMHC-I (5, 6) , the nature of the pMHC-I structure (7) (8) (9) , and the total number of pMHC-I presented by APCs (10, 11). On the other hand, various properties specific to the host T CD8+ also play a role, including their relative diversity, precursor numbers, functional avidity, recruitment rate, ability to expand, and propensity to compete with one another (2, 5, (12) (13) (14) (15) . However, the relative importance of each of these factors is still uncertain.
Another issue that remains unclear is how variations in viral dose affect the T CD8+ ID hierarchy. Probst et al. (16) addressed this question by examining how the ID hierarchy changed in response to increasing doses of lymphocytic choriomeningitis virus (LCMV). Specifically, these investigators found that the ID hierarchy is directly contingent upon viral dose, with one T CD8+ response (to NP 396 ) dominant at low viral doses but another (to GP 33 ) dominant at high viral doses. Whether such findings extend to other viral systems is unknown, but recent mathematical modeling suggested that alterations in Ag dose should routinely affect ID hierarchies and that immunodominant epitopes will increasingly outcompete subdominant ones as Ag dose increases (17).
In the current study, we addressed the issue of how Ag dose affects the ID hierarchy to influenza A virus (IAV) by using a combination of experimental and modeling approaches. To begin, we selected an i.p. route of administration for IAV rather than using the conventional intranasal route, which supports productive infection of virus (18) and, therefore, results in a highly saturated viral dose even at very low inoculation doses (M.T. Sanders and W. Chen, unpublished observations). In contrast, i.p. administration of IAV leads to a nonproductive infection due to lack of a specialized lung-specific tryptase that is necessary for host cleavage of the viral hemagglutinin protein and subsequent virion release. Consequently, the dose of viral inoculation with i.p. administration is more likely to reflect the true Ag dose available for presentation, a point that we were keen to exploit to address how changes in viral dose affect the ID hierarchy of T CD8+ . We subsequently challenged mice with increasing amounts of IAV over a five-log range and observed that, as IAV dose increases, there is a generalized expansion in the total numbers of subdominant and immunodominant T CD8+ , as well as a notable switch in the ID hierarchy, whereby NP [366] [367] [368] [369] [370] [371] [372] [373] [374] (NP 366 ) is replaced as the immunodominant epitope by PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] (PA 224 ). To better understand these results, we used a stochastic model to simulate T CD8+ responses to IAV infection under a range of scenarios. By doing so, we found that relative epitope presentation is the critical influence on the T CD8+ ID hierarchy at low viral doses, enabling the T CD8+ specific for the more abundantly presented NP 366 epitope to dominate the response. However, at high viral doses, relative T CD8+ avidity (defined as the probability that a T CD8+ proliferates upon encountering its cognate Ag) and precursor numbers become important, and the PA 224 T CD8+ usurp NP 366 T CD8+ as a result.
Materials and Methods

Mice, viruses, and infection
B6 female mice were purchased from Walter and Eliza Hall Institute animal services (Kew, Australia), and animals were generally used at 8-12 wk of age. Experiments were conducted under the auspices of the Austin Health Animal Ethics Committee and conformed to the National Health and Medical Research Council Australian code of practice for the care and use of animals for scientific purposes. IAV (A/Puerto Rico/8/34 [H1N1], PR8) was grown in 10-d embryonic chicken eggs. The titer of infectious virus was determined by plaque formation on confluent monolayers of MadinDarby canine kidney cells, as previously described (19). Mice were infected by injecting IAV i.p. at doses ranging from 10 3 to 10 8 PFU.
Abs and peptides
For flow cytometry, FITC-labeled anti-IFN-g and Cy-Chrome-labeled anti-CD8a were purchased from Becton Dickinson (North Ryde, Australia). Peptides were procured and characterized by the Biologic Resource Branch, National Institute of Allergy and Infectious Diseases (Rockville, MD) and were kind gifts from Drs. Jonathan Yewdell and Jack Bennink (National Institute of Allergy and Infectious Diseases, National Institutes of Health). They included NP 366 (ASNENMETM), PA 224 (SSLEN-FRAYV), PB1F2 [62] [63] [64] [65] [66] [67] [68] [69] [70] (PB1F2 62 ; LSLRNPILV), NS2 114-121 (NS2 114 ; RTFSFQLI), and PB1 703-711 (PB1 703 ; SSYRRPVGI).
Intracellular cytokine staining
For intracellular cytokine staining (ICS), splenic and peritoneal cells from infected animals were suspended in 200 ml RPMI 1640 with 10% FCS at 1.5-2 3 10 6 cells/well in round-bottom 96-well plates. Peptides were added to cells at a final concentration of 1 mM, and cells were incubated with peptides for 2 h at 37˚C and then for 4 h with brefeldin A (BFA; Sigma-Aldrich, St. Louis, MO) at 10 mg/ml. Cells were stained with CyChrome-labeled anti-CD8a mAb at 4˚C for 30 min, washed, and fixed with 1% paraformaldehyde in PBS at room temperature for 20 min, and then further stained with fluorescein-anti-IFN-g in PBS containing 0.4% saponin (Sigma-Aldrich). Stained cells were acquired on a FACSCalibur (Becton Dickinson) and analyzed using FlowJo software (TreeStar, Ashland, OR). As a negative control, cells were not exposed to peptide to establish the background level of the ICS assay. This background value was subtracted from each of the peptide-stimulated wells to obtain a peptide-specific level of response.
Estimates and modeling of Ag-presentation levels
Our method to assess the kinetics of Ag presentation using BFA was described previously (12, 20, 21). The resulting data from these assays were used to obtain quantitative estimates of the relative presentation levels and speed of epitope presentation (3, 12) . To do so, we assumed that the proportion of T cells stimulated in each well in the Ag-presentation assay was a direct reflection of peptide density presented on the surface of the APC. Ag-presentation data from BFA-kinetics assays were used to derive the time at which 50% of the T cell activation was achieved (K m ), as well as the maximum Ag presentation levels (A max ). To obtain A max for each epitope, we assumed that the maximal presentation on an APC is proportional to the amount of epitope-specific T cells stimulated at the highest level of presentation in the BFA-kinetics assay (3, 12) (W. Chen, unpublished observations). The resultant estimates are summarized in Table I and were used to feed the two parameters of a Hill function describing Agpresentation levels over time.
Mathematical modeling of T CD8+ ID
Two mathematical models were explored. Model 1: Handel and Antia model. We adapted the model of Handel and Antia (22) to simulate the five major T CD8+ responses following primary IAV infection. This model considers viral dose (V), pMHC-I on APCs (P i ), and two populations of T CD8+ naive epitope-specific T CD8+ (T i ) and activated (or effector) T CD8+ , (T i *), where i is the index representing the five epitopes. The model is given as a system of ordinary differential equations that deterministically describe the T cell dynamics as follows:
In this model, virus grows exponentially with rate r and is eliminated via activated T CD8+ at rate k i . Ag presentation for a given epitope is modeled as proportional to the amount of virus with a epitope-specific scaling factor f i , and is eliminated at a fixed rate d i . pMHC-I activate Ag-specific T CD8+ at rate a i . These activated T CD8+ proliferate at rate g i via clonal expansion. Because the model describes only the expansion phase, it does not include the death of Ag-specific T CD8+ . We used the same parameter values that were used by these investigators except that we set r to 0 because we were modeling a nonreplicative i.p. infection, varied f i over a 3-log range (10 2 -10 5 ) to simulate the experimental increase in viral dose; and adjusted f i to reflect observed differences in A max between epitopes ( Table I ) (note that K m estimates cannot be used in this model because the model assumes a linear interaction between T cells and Ag-presentation level). The entire list of parameter values is provided in Table II . Model 2: Individual-based model. We refined an individual-based model (IBM) proposed by Scherer et al. (17) , which is a stochastic version of the seminal model proposed by de Boer and Perelson (23), for which a general deterministic population-based approach was used to describe the responses of Ag-specific T CD8+ following interaction with APCs. This IBM simulates the individual encounter of naive T CD8+ with APCs over time, and each encounter-as well as its downstream sequelae, such as T CD8+ activation, proliferation, and killing-is described as a separate probabilistic event. In this way, the model simulates thousands of individual stochastic events that occur simultaneously at each time point to eventually produce an in silico version of the T CD8+ response at 7 d. The novelty of our implementation of the original IBM (17) is that we modeled Ag presentation as a dynamic process to take into account our previous experimental data on the kinetics of influenza epitope presentation (3, 12) .
Our IBM separately models three aspects of IAV infection and the subsequent immune response: infected cells, APCs, and T CD8+ . The model begins with a starting number of virally infected cells. Because we are simulating what happens when different amounts of virus are inoculated via a nonproductive i.p. route, the model begins with a starting number of virally infected cells that was varied according to initiating viral dose and did not increase thereafter. APCs were then generated from the population of infected cells at a constant rate (s) and were also assumed to die at a constant rate. Each APC was allowed to be able to bind up to 150 T CD8+ at any given time, as suggested by imaging experiments showing that between 10 and 300 T cells can engage with a single APC simultaneously (24). The number of pMHC-I for any given epitope was described by a Hill function based on estimates of K m and A max , as detailed above. Previous evidence suggests that naive T CD8+ occur at a frequency of 10-2000, depending upon the particular T CD8+ specificity (25-29). Therefore, we selected a precursor frequency of 500 cells as our default starting value, because this value was roughly in the middle of the observed experimental range. Similarly, we estimated that each of these naive T CD8+ scans 50 APCs/d, a range chosen based upon data from live T cell imaging (22, 30). For each scanning event, a T CD8+ has a given probability of subsequently binding to the APC as determined by the level of Ag presentation. After binding, each T CD8+ interacted with the APC for an average of 1 h before dissociating. In reality, experimental data on the dynamics of the interactions between APCs and T CD8+ suggest that T CD8+ first engage in multiple, short encounters and then in longer interactions that last up to 30 min (31), but we condensed these multiple encounters into one longlasting interaction for simplicity. During this interaction, each Ag-specific T CD8+ has a given probability of becoming activated, which we ascribed to a single parameter that we termed "functional avidity." In reality, this avidity is likely to reflect multiple factors, including the nature of APC:T CD8+ signaling (e.g., costimulatory signals via CD28), as well as intrinsic properties of the T CD8+ itself (24, 32, 33). To differentiate dominant from subdominant responses, we assumed, as did Scherer et al. (17) , that dominant responses have a higher functional avidity. Following successful activation, a T CD8+ dissociated from its APC and went through multiple rounds of proliferation. In our model, the first round of proliferation was slow, based on experimental evidence that T cells only start to proliferate after an initial lag phase ∼1 d. Thereafter, proliferation occurred every 6 h, with the default number of total proliferation rounds set at 8, which was chosen based on experimental evidence that T CD8+ go through 5-10 rounds of programmed proliferation without the need for re-exposure to Ag (34). The model also incorporated the spontaneous death of T CD8+ at a constant rate d that was based on previously published estimates (35). After proliferation, T CD8+ became effector cells and cleared virally infected cells at a rate k. In this way, the number of infected cells followed a decline curve from t = 0 determined by the total number of effector T CD8+ and the clearance rate k.
Thus, our refined IBM uses multiple parameters to simulate the T CD8+ response following i.p. IAV infection. In theory, simulations using our IBM could be performed by allowing the values of multiple parameters to run free simultaneously. However, with so many parameters to vary, the number of possible outcomes that the model could describe is very large, and the simulations become computationally intractable. For this reason, we fixed the majority of the parameters to known values based upon existing experimental or computational estimates found in the literature (Table III) . Where such estimates were lacking, as was the case for the dynamics of viral-infected cells and the rate of APC generation s, or where the literature-based estimates varied considerably, as was the case for the APC death rate or the number of cycles of programmed T CD8+ proliferation, we performed preliminary analyses to tune the model and obtain estimates that enable a realistic reproduction of the T CD8+ ID hierarchy (see Discussion).
Approximate Bayesian computation
We used approximate Bayesian computation (ABC) algorithms to estimate parameters of the IBM. These algorithms are particularly useful for obtaining estimates in situations in which standard techniques, such as those based on likelihood functions, are no longer applicable or difficult to Table IV  10   2   -10   4   Table IV (20, 63, 64) Time at which the epitope presentation reaches 50% of the maximum Table I  1-48 h  Table I  (2, 3, 12) APC death rate
compute, as is the case for complex stochastic models, such as our IBM (36, 37). Provided that the underlying model is close enough to the real system and the experimental observations are well captured by the summary statistics used to estimate the model parameters, this approach provides reliable and satisfying results. For example, previous applications of ABC showed that ABC estimates are accurate in scenarios in which likelihoodbased inference methods are also possible (38) , and various groups have used ABC to estimate the evolutionary rates of human or bacterial populations (39, 40) , the transmission dynamics of Mycobacteria tuberculosis (41) , and the fitness cost associated with bacterial drug resistance (36). In keeping with Bayesian statistics, ABC parameter estimates are represented as a posterior distribution that provides information on the likelihood that the unknown parameter falls within a certain range of values. This range is represented as a 95% credibility interval (CI), and from this interval one can obtain an idea of the reliability of the ABC estimates. With all of the other IBM parameters fixed (Tables II, III) , we used ABC to estimate Ag-expression levels, T CD8+ precursor numbers, and relative T CD8+ avidities. The ABC algorithm used in this work was the rejection algorithm (40), where we corrected the estimates using a linear-regression method as previously suggested (42), and the algorithm was implemented using the statistical package R (43) . ABC algorithms approximate the data D by a set of summary statistics SD, which can be derived from observations. The idea is then to sample parameter values from the prior distribution and compare the result of the simulations with the observed data via summary statistics. The comparison is performed by defining a distance function that reports on the similarity between simulated and observed data sets. We used as summary statistics the five Ag-specific T CD8+ counts observed within the spleens of mice 7 d after i.p. infection with different doses of IAV. For each parameter set, we simulated the primary infection six times, because this was the minimal number of mice used for our in vivo experiments, and then compared the observed and simulated mean values. As a distance function, we considered the Euclidean distance are the corresponding simulated values, and var(Ti) is the variance for each response measured from the six repeated simulations with the same parameter values. The prior distribution for Ag-presentation levels and T CD8+ precursor numbers was chosen as a uniform distribution with values ranging between 0 and infinity (in reality, a very large number), whereas the prior distribution for T CD8+ avidity ranged between 0 and 1.
Results
Increasing viral dose during primary IAV infection causes a generalized expansion in T CD8+ responses and changes in the ID hierarchy
To address the role of Ag dose in the overall primary T CD8+ response, we measured Ag-specific T CD8+ numbers 7 d after i. , and 10 8 PFU (data not shown). As shown in Fig. 1A , the total number of splenic T CD8+ for both immunodominant and subdominant determinants increased as viral dose increased. Specifically, only a few hundred T CD8+ were elicited for each determinant at the lowest viral dose (10 3 PFU), and this increased approximately two and three orders of magnitude at the highest dose (10 8 PFU) for the subdominant and dominant determinants, respectively. In support of these trends, there was a statistically significant dose-dependent increase in immune responses for each epitope (p , 0.05 for T CD8+ responses of each determinant measured at different viral doses, Wilcoxon signed-rank test), with the exception of some responses between 10 6 and 10 7 and 10 7 and 10 8 PFU, for which we observed only a modest increase with viral dose, indicating likely saturation of the response. These data suggest that, as IAV viral dose increases, there is a generalized expansion of T CD8+ responses and no apparent effect of dominant responses supplanting subdominant ones via competition, as previously postulated (17).
To specifically assess the effect of increasing viral dose on the ID hierarchy, we examined the relative contribution of each of the five Ag-specific T CD8+ populations to the total immune response in the above experiment (Fig. 1B) . At the lowest viral dose (10 3 PFU), all five determinants elicited a similar level of response. Of note, at this dose the overall magnitude of T CD8+ responses was close to background levels, and there was large variation in the ID hierarchy between individual mice, which likely reflects the stochastic nature of the interaction between T CD8+ and APC at very low Ag levels. Beyond 10 3 PFU, an interesting picture emerged. Notably, the relative contribution of PA 224 T CD8+ progressively increased as viral dose increased; NP 366 T CD8+ showed the opposite response, peaking at an IAV dose of 10 4 -10 5 PFU and decreasing thereafter. Meanwhile, the relative contribution of the three subdominant T CD8+ responses tended to remain constant. Overall, the effect of these changes was to produce a reversal in ID: at lower viral doses (10 5 PFU), the NP 366 -specific T CD8+ response was dominant over PA 224 (p value , 0.05, Wilcoxon signed-rank test), whereas at higher doses (10 8 PFU), PA 224 T CD8+ were dominant over NP 366 (p , 0.05, Wilcoxon signed-rank test). This switch in ID was even more striking among peritoneal T CD8+ (Supplemental Fig. 1 ), for which similarly statistically significant differences were observed. Together, these results indicate that the relative contribution of different Ag-specific T CD8+ to the overall response following primary IAV infection is dependent upon viral dose.
A simple mathematical model fails to explain the observed changes in ID hierarchy
Previously, we found that NP 366 and PA 224 were presented by APCs at different rates and efficiencies (3, 12) . We hypothesized that this difference in Ag presentation might explain why an increase in IAV dose leads to a change in the primary ID hierarchy. To test this idea, we used the mathematical model proposed by Handel and Antia (22), which is predicated on the assumption that T CD8+ activation varies linearly with Ag presentation and was previously shown to successfully explain changes in T CD8+ ID hierarchy between primary and secondary IAV infection.
To begin, we obtained estimates for the maximal relative presentation level and rate of presentation for each epitope (Table I) using our published Ag-presentation data for NP 366 , PA 224 , PB1F2 62 , and NS2 114 (3, 12) , as well as more recent results for PB1 703 (W. Chen, unpublished observations) (Materials and Methods). We found that NP 366 -specific T CD8+ were activated and rapidly reached half-maximal stimulation (K m ) after only ∼1 h. In contrast, PA 224 presentation was much slower (K m = 8 h) and less effective, stimulating only a minority of PA 224 -specific T CD8+ , whereas the rates and relative presentation levels of the subdominant epitopes NS2 114 , PB1F2 62 , and PB1 703 fell in between NP 366 and PA 224 .
Taking into account these differences in relative presentation levels, we used the maximum relative presentation level to estimate the rate f at which Ag are presented on the surface of APC in the Handel and Antia model (Materials and Methods) (Table II) . We found that the Handel and Antia model recapitulated our observation that an increase in viral dose causes an overall expansion in the absolute number of Ag-specific T CD8+ at day 7 ( Fig. 2A) . However, the model failed to reproduce the change in ID hierarchy that we observed experimentally; instead, it produced a scenario whereby all five Ag-specific T CD8+ under study contributed equally at the highest Ag dose (Fig. 2B) . These results suggested that a simple linear dependency between Ag-presentation levels and T CD8+ responses is, by itself, insufficient to explain what happens as viral dose increases.
IBM recapitulates the Ag dose-dependent trends in ID hierarchy and highlights the importance of rapid and effective NP 366 presentation in its immunodominant status at lower Ag doses
We next evaluated and adapted a previously published IBM (17) that takes into account differences in Ag presentation, as well as the dynamic and stochastic interactions between T CD8+ and APCs (Materials and Methods). In our modified IBM, Ag presentation occurs as a saturating function over time at a rate that is specific for each individual epitope.
To model the experimental increase in viral dose, we first ran a series of simulations in which the total number of infected cells (and hence the number of APCs) was allowed to increase, but the Ag-presentation level/APC remained constant. For these simulations, we arbitrarily assumed a value of n = 500 precursor cells for each Ag determinant, based on previous estimates of viral Agspecific T CD8+ precursor numbers that ranged from 10 to 1200 (14, 25). Similar to our earlier modeling, this reproduced the generalized expansion in the total number of responding T CD8+ response as viral dose increased, but it failed to reproduce the observed ID changes (Supplemental Fig. 2) . Therefore, we ran another series of simulations in which both the level of Ag presentation/APC and the total number of infected cells were allowed to rise with increasing viral dose. The simulations showed a generalized expansion in the absolute numbers of Ag-specific T CD8+ as Ag dose increased (Supplemental Fig. 3 ). Importantly, they also demonstrated dose-dependent trends in ID hierarchy that mirrored those seen experimentally (compare Fig. 3A and 3B) . Namely, at very low Ag levels, all five determinants showed a similar response; as Ag levels increased, NP 366 -specific T CD8+ rose to dominance and then diminished, the proportion of PA 224 -specific T CD8+ gradually increased, and the contribution of the three subdominant T CD8+ decreased. Notably, the dominant status of NP 366 -specific T CD8+ at low Ag levels was contingent upon the rapid and highly effective presentation of NP 366 (Table I) , because any downregulation of this presentation in the modeling failed to replicate the experimental response for NP 366 .
Higher precursor numbers and/or higher avidity can explain the rise of PA 224 T CD8+ to ID at increased Ag doses Despite the success of the above modeling in describing the general trends observed for the IAV T CD8+ hierarchy as a function of viral dose, one aspect that the simulations failed to reproduce was the final switch in ID: instead, PA 224 -and NP 366 -specific T CD8+ remained codominant at the highest Ag levels (Fig. 3) . Therefore, we under- First, we studied the role of T CD8+ precursor numbers in the simulations. To begin, we modeled scenarios with either low (n = 50) or high (n = 1000) numbers of T CD8+ precursors for each determinant (instead of n = 500 cells, as described earlier). Fig. 4 shows the relative proportion of each Ag-specific T CD8+ response at day 7 when the precursor numbers were set either low (Fig. 4A) or high (Fig. 4B) . In both scenarios, plotting the average trend across hundreds of simulation runs provided very similar results to each other, although, interestingly, the distribution of individual simulations was different. Specifically, when precursor T CD8+ numbers were lower, the simulated results showed great variability; conversely, when precursor T CD8+ numbers were higher, the modeling followed a much tighter distribution. This makes intuitive sense because, regardless of the prevailing Ag-presentation levels, any reduction in the number of precursor T CD8+ will lower the probability that a T CD8+ encounters an APC and, thus, increase the stochasticity of the response.
In any case, these simulations failed to improve upon our previous modeling with 500 precursor T CD8+ /epitope (Fig. 3B) ; therefore, we examined how relative differences in epitopespecific precursor numbers might affect the simulated T CD8+ response. To do so, we again simulated two scenarios: one in which the ratio of PA 224 /NP 366 precursors was 0.2 (100:500) and another in which the ratio was 2 (1000:500). Reducing the PA 224 precursor numbers resulted in greater discordance between the simulations and experimental results (Fig. 4C) : specifically, the simulated PA 224 response decreased to the level of the three subdominant epitopes, whereas the NP 366 response remained dominant throughout. In contrast, increasing the PA 224 precursor number almost exactly reproduced the ID hierarchy that we observed experimentally, including the switch in ID at higher Ag doses (compare Figs. 4D and 3A) , indicating that T CD8+ precursor frequencies can indeed have a decisive influence upon T CD8+ ID hierarchies. This seems logical, because raising T CD8+ precursor numbers increases the likelihood of a T CD8+ :APC encounter and, hence, the probability of T CD8+ activation and subsequent proliferation.
Next, we examined how relative differences in T CD8+ avidity might affect the T CD8+ response. To do so, we allowed the avidity of PA 224 -specific T CD8+ to be slightly higher than that of NP 366 -specific T CD8+ (earlier we had assumed that the two were equivalent; Table III), while maintaining the precursor frequencies for all epitopes at the original value of n = 500 cells. As shown in Fig. 5 , this minor alteration was sufficient to allow the modeled ID hierarchy to precisely recapitulate the one observed experimentally, including the ascendance of PA 224 -specific T CD8+ to sole ID at the highest Ag levels (compare Figs. 3B and 5 ). The importance of T CD8+ avidity was further highlighted by simulations in which we allowed the avidity of PB1 703 , NS2 114 , and PB1F2 62 T CD8+ to be equivalent to that of NP 366 and PA 224 : in this case, these previously subdominant responses rose to codominance, reaching similar saturation levels as for NP 366 and PA 224 at higher Ag levels (data not shown). Taken together, these results suggested that, once Ag levels were no longer limiting, relative differences in T CD8+ avidity critically shaped ID. Again, this makes sense, because avidity directly determines the probability of T CD8+ activation and, hence, the likelihood of proliferation.
Estimates of pMHC-I numbers, T CD8+ precursor numbers, and avidities
In modeling the various scenarios above, in each case we made different assumptions about the parameter values for Ag presentation, T CD8+ precursor numbers, and avidities before the simulations were actually performed. Although useful for illustrating (Tables II, III) . Each dot represents the mean values of six repeated simulation runs with identical parameter settings, and continuous lines represent the fitted splines. The y-axis indicates the proportion of Ag-specific T CD8+ of the total response at day 7, and the xaxis shows the combined per-APC Ag-presentation level for the five epitopes of interest.
the potential role of each parameter in shaping ID, such an approach did not, for example, indicate whether the ID of PA 224 T CD8+ at high viral doses was most likely due to greater avidity, greater precursor numbers, or both. ABC is a statistical method that allows de novo inference of parameter estimates in situations in which standard techniques are not applicable or difficult to compute, as is the case for complex stochastic models, such as our IBM (36, 37). Therefore, we applied ABC to our IBM-based simulations to formally estimate pMHC-I levels, T CD8+ avidity, and precursor numbers (Materials and Methods), as well as to gain additional insights into the underlying basis for IAV ID.
The resultant ABC-derived estimates (Tables IV-VI) were revealing. First, the method provided clear estimates for the average number of pMHC-I likely to be found on an individual APC as viral dose increased. Specifically, the method estimated that the total number of pMHC-I/APC (for the five determinants under study) increases from 75 at a dose of 10 3 PFU IAV (95% CI: 44-144) to 5303 at a dose of 10 8 PFU IAV (95% CI: 4289-5808) (Table IV) . Second, the method predicted that the median avidity of PA 224 T CD8+ is ∼40% higher than that of NP 366 (Table V) . Third, the method estimated that the median precursor number of PA 224 T CD8+ is higher than that of NP 366 T CD8+ (Table VI) , consistent with previous experimental estimates (14), although the difference was only ∼25%, and the large CIs suggested that a wide range of possible precursor values is able to produce a good fit with the experimental data. Taken together, the latter two results are, nevertheless, in agreement with our earlier ad hoc modeling and suggest that the increase in PA 224 T CD8+ to ID at high viral doses is likely due to a combination of greater avidity and higher precursor numbers.
Discussion
The amount of inoculating Ag is an essential variable in immunization design. Therefore, understanding how Ag dose affects subsequent T CD8+ responses is important to the rational optimization of T CD8+ -based vaccines. We began this study by examining how Ag dose affects the overall T CD8+ response to IAV. Not surprisingly, other investigators examined this general question before, although, interestingly, the results have not been wholly consistent. For example, infecting BALB/c mice with 1,000, 5,000, or 25,000 live Listeria monocytogenes failed to alter the magnitude of the immunodominant LLO 91-99 T CD8+ response in vivo (44) , but other investigators found that infection with 10 7 attenuated L. monocytogenes bacteria elicited a 5-fold increase in responding T CD8+ compared with 10 5 bacteria (45). Similar to this second study, Murata et al. (46) reported that T CD8+ responses to a Plasmodium yoelii epitope encoded by engineered IAV or vaccinia virus were enhanced by increasing the immunizing viral dose. Wherry et al. (47) also demonstrated that the T CD8+ response size to epitopes from IAV's nucleoprotein, as well as OVA, is proportional to epitope expression, although they varied Ag expression not by altering overall viral dose but by using different vaccinia virus-expression constructs. All three of these latter reports are consistent with the results of our current study, which demonstrates a significant increase in the total number of IAVspecific T CD8+ as viral dose increases (Fig. 1A) . However, it should be noted that, beyond a certain Ag dose, significant T CD8+ expansion ceased (see especially Supplemental Fig. 1A) , which is consistent with earlier findings indicating that once a certain threshold density of epitopes is reached, saturation of the T CD8+ response occurs (46) (47) (48) .
Having a broad immune response against multiple T CD8+ epitopes is believed to confer better antiviral protection (49) and, therefore, is a desirable goal for T CD8+ -based vaccines. Scherer et al. (17) predicted that the repertoire of T CD8+ is likely to constrict as Ag levels increase: specifically, using an IBM they reported that subdominant responses will be sequentially outcompeted to the point that only one immunodominant response remains. If this is true, then increasing Ag dose in vaccines might actually sacrifice immune breadth (despite optimizing depth) and have deleterious consequences for immunity. Interestingly, our experiments did not bear out these predictions. Instead, we found that, even at the highest Ag doses where saturation of the immunodominant T CD8+ responses became evident, the total number of T CD8+ directed against subdominant epitopes continued to increase (Fig. 1A) . Notably, when we ran simulations assuming very low numbers of T CD8+ binding sites per individual APC (,10), we obtained predictions similar to those of Scherer et al. (data not shown), suggesting that competition phenomena can be relevant if T CD8+ access to APCs is extremely limited. However, professional APCs contact as many as 50-300 T cells at any one time (24, 30), suggesting that the number of T cell binding sites/APC is in reality much .10 and that T cell competition, therefore, is more likely to be the exception, rather than the rule, in primary responses.
Consistent with the findings of Probst et al. (16) in relation to LCMV, we report that T CD8+ ID hierarchies following IAV infection are clearly dependent upon Ag dose. Interestingly, at low viral doses, the immunodominant T CD8+ against both LCMV and IAV are directed toward the epitopes that show the most rapid presentation kinetics (NP 396 and NP 366 , respectively). This suggests that relative differences in Ag presentation powerfully shape the primary ID hierarchy when Ag supplies and, hence, the number of pMHC-I, is limited. In our case, this was most readily demonstrated by the observation that NP 366 T CD8+ dominate over those specific for PA 224 , whose presentation is much slower and less abundant (Table I) . Indeed, when we performed simulations in which either the K m or A max for NP 366 presentation was reduced, the dominance of NP 366 T CD8+ at low Ag levels was lost (data not shown). Moreover, when comparing the subdominant T CD8+ responses at low viral doses, we observed a similar trend: namely, the epitope with the highest and most rapid presentation (NS2 114 ) elicited the more robust response (Fig. 3) . In contrast, when Ag levels are plentiful, it appears that these relative differences in Ag presentation lose functional significance, as exemplified by the rise of PA 224 to ID, despite its poor presentation. Intuitively, this makes sense because one would expect that as both the number of pMHC-I and the total number of APCs increase, the overall level of pMHC-I for all five epitopes will be in relative excess and no longer a limiting factor to T CD8+ activation. Thus, the influence of Ag presentation on ID appears to vary depending upon Ag dose. This variability might explain why relative differences in Ag presentation, in the context of the ID hierarchy following primary IAV infection at least, were shown by some investigators to have a decisive role (50), whereas others assumed them to be of little consequence (36).
At high viral doses, the alteration in the T CD8+ ID hierarchy to LCMV and IAV appears due to different causes. For LCMV, higher viral doses lead to chronic infection and apparent exhaustion of the NP 396 response with subsequent ID by GP 33 T CD8+ (16). For IAV, we found that the rise of PA 224 T CD8+ at higher Ag doses could be explained by both superior functional avidity and precursor numbers. With regard to functional avidity, it was shown that inefficiencies in precursor cell recruitment, as well as their subsequent expansion, can render T CD8+ responses subdominant (14). Our simulations varying the relative avidities of PB1 703 , NS2 114 , and PB1F2 62 T CD8+ were consistent with this notion, because the subdominance of these responses at high Ag levels was strictly dependent upon their having a lower avidity than NP 366 and PA 224 (Table III) . Moreover, our results indicate that the converse might also apply (i.e., that highly efficient recruitment and/or expansion can lead to ID, as evidenced by our results with PA 224 ). Taken together, the relative functional T CD8+ avidity plays a critical role in tuning the proportional response toward any given peptide determinant either up (for dominant T CD8+ ) or down (for subdominant T CD8+ ), provided that Ag levels are not limiting. As for precursor numbers, their role in determining primary ID hierarchies has been unclear. Using double tetramer-staining techniques and TCR diversity assays to estimate Ag-specific T CD8+ numbers, multiple studies showed a positive correlation between naive precursor numbers and the resultant primary T CD8+ response following infection with IAV and LCMV (28, 49-51). However, others failed to observe such trends (14, 29). Our finding that higher precursor numbers of PA 224 T CD8+ are likely to contribute to the ID of PA 224 at high Ag doses, albeit in probable combination with a higher avidity, provides two insights. First, the role of precursor numbers in shaping ID hierarchies may only be apparent when Ag doses are high. Again, this makes intuitive sense because, at high Ag doses where the number of APCs is in relative excess and the number of T CD8+ precursors is a limiting factor, increasing precursor frequency should raise the likelihood that a T CD8+ will interact with an APC bearing its cognate epitope. In contrast, at low Ag doses, where the number of T CD8+ is in relative excess and it is the number of APCs that critically limits the T CD8+ response, increasing precursor frequency should have minimal effect. Second, even when Ag levels are sufficient, higher precursor numbers alone are unlikely to guarantee ID because avidity must also be considered, as elegantly highlighted by other investigators (14). Indeed, the large CIs that we obtained when estimating precursor numbers are consistent with previous findings that T CD8+ precursor numbers by themselves do not predict ID hierarchy (14, 29).
One possible explanation for the changes in ID hierarchy that we observed is that alterations in Ag dose differentially affect the kinetics of individual T CD8+ responses. For example, the apparent decrease in the NP 366 T CD8+ response at higher viral doses at day 7 might simply reflect a shift in the peak of the NP 366 T CD8+ response to a different time point. Indeed, the T CD8+ response to NP 366 was observed to occur later than for PA 224 following both intranasal and i.p IAV infection (2, 14) . Similarly, the ID hierarchy to LCMV also changes over the course of an acute infection (52) . Thus, there remains a possibility that our day-7 ex vivo assessment missed the peak of the NP 366 T CD8+ response and that these cells, in fact, remained as dominant as PA 224 T CD8+ at higher viral doses. A related argument could be made for PA 224 T CD8+ at lower viral doses. To examine this issue, we experimentally assessed the T CD8+ response at different time points These estimates were based on experimental data for 10 6 PFU of IAV, because these estimates showed the minimum error from a cross-validation test. Data represent median (95% Bayesian CI). (from days 4 to 9) across a range of viral doses (10 4 -10 8 PFU). Importantly, we found that the peak response consistently occurs between days 7 and 9 and that the overall ID hierarchy does not change (data not shown). This was further supported by additional IBM that showed that, even though the peak of the T CD8+ response moved from day 6 to 9 at low versus high Ag levels, respectively (Supplemental Fig. 4 : compare peak responses in A-D), the overall ID hierarchy remained stable across time for any given Ag dose (Supplemental Fig. 4 : compare the relative T CD8+ response within each panel). Taken together, these results suggested that our ex vivo observations at day 7 truly reflected a dose-dependent change in hierarchy and not simply differential kinetics.
Given that ID reflects a complex interplay between complex factors, it is hardly surprising that mathematical modeling has been used as a means to better understand ID (17, 22, 23, 53) . Indeed, it was suggested that, in the future, ID research will increasingly rely upon such modeling (3) . In this study, we found that complex stochastic modeling enables the successful simulation of our experimental findings, and it provides novel insights into the underlying basis for ID hierarchy establishment at different Ag doses. Complex models are more likely to resemble reality compared with simple simulations, but they tend to have a higher number of parameters and, therefore, can be more difficult to tune to the correct region of higher-dimensional parameter space. Our use of advanced Bayesian statistics enabled the estimation of multiple immune parameters (pMHC-I densities, T CD8+ avidities, and naive precursor frequencies) for five IAV epitopes, armed only with the experimental details of relative Ag presentation and day-7 T CD8+ responses. With recent technological developments, some of these parameters can now be estimated experimentally, be it through tetramer enrichment to enumerate naive precursors (29, 54), the use of pMHC-I-specific mAb and HPLC fractionation to elucidate epitope densities (20, 55, 56) , and tetramer/BrdU-based methods to analyze recruitment rates (14). Nevertheless, such approaches remain technically challenging, prone to underestimation, and not always readily applicable given the limited availability of key reagents.
Therefore, mathematical modeling offers an alternative approach to parameter estimation, and the framework used in our study should be readily adaptable to other contexts (e.g., the study of non-IAV infections or CD4 + T cell dynamics). Notably, comparison between our novel modeling-based estimates and those obtained experimentally reveals broad agreement. Specifically, our estimates of between ∼5000 and 6000 pMHC-I/APC for the five major IAV epitopes at the highest viral dose is very similar to the HPLC-derived estimate of ∼7000 pMHC-I previously reported for the five major IAV epitopes in the BALB/c mouse system (20). Similarly, our estimated median precursor frequencies were consistent with the published tetramer-based estimates of La Gruta et al. (14) , which also indicated that there are more naive PA 224 T CD8+ than NP 366 T CD8+ , although our estimates were higher and had broad Bayesian CIs. Finally, our estimates of functional avidity, although not directly comparable with any existing experimental data, are in keeping with evidence that PA 224 T CD8+ display a broader diversity of TCRs (14, 26, 32, 33) and, thus, may have a greater probability of proliferating upon Ag encounter.
Taken together, our work suggests that mathematical modeling is an important adjunct to the experimental dissection of ID. Of course, it is important to emphasize that mathematical modeling of ID is still in its relative infancy and, just like many of the cuttingedge experimental techniques mentioned earlier, it has its own set of restrictions and caveats. Looking ahead, there is great scope to build upon the approaches that we developed in this study, and this is discussed below.
First, it will be interesting to see how well our modeling translates to the context of a productive infection. For this study, we specifically chose the nonproductive i.p. route of infection, because we reasoned that the dose of viral inoculation would be more likely to reflect the true Ag dose available for presentation, and it would be more directly relevant to standard influenza immunization practices that rely upon nonproductive i.m. injection. However, because much of the research literature on ID uses productiveinfection models, testing and validating our IBM and ABC methods in these other systems will be important.
Second, there is undoubtedly scope to further improve the IBM. Indeed, despite its apparent success in recapitulating the observed experimental outcomes, the IBM in its current form has several key limitations. Chief among these is the need to preassign values to some of the various model parameters (Table III) . In many cases, one can assign these values with some confidence, given existing estimates in the experimental literature. However, in other cases, such estimates either vary considerably (e.g., APC death rates and number of programmed T CD8+ proliferation rounds) or simply do not exist (e.g., APC recruitment rates). To overcome this challenge, we ran preliminary tuning analyses to choose "best guess" parameter values that enabled the simulations to resemble the major features of the observed experimental responses (Materials and Methods). For example, our tuning analyses indicated that both the timing of the T CD8+ response peak and the overall number of responding T CD8+ (but not the ID hierarchy itself) were sensitive to changes in either the number of rounds of programmed T CD8+ proliferation or the APC recruitment rate (data not shown); we eventually chose values whose simulations best approximated our experimental findings. In the future, as experimental innovations occur, estimating parameters such as these will hopefully become more accurate and less dependent upon guesswork. Another key limitation of the IBM is the need to break down what is an inherently complex process into a simplified set of defined parameters. Although our IBM took into consideration almost 30 parameters, it failed to capture many aspects of the immune response that one would ideally like to include in future modeling efforts. For instance, the model does not take into direct consideration the role of inflammation, which might be expected to impact upon the T CD8+ response in multiple ways, especially as the viral dose is altered. Specifically, inflammation, through the action of cytokines, such as IFNs and TNF-a, is likely to enhance MHC-I and costimulatory molecule expression on APCs, as well as to increase T CD8+ survival (57) , through the upregulation of molecules such as 4-1BB. In this way, one can envisage that, as viral dose increases, increased levels of inflammation will dynamically impact upon various parameters that already exist within our IBM, including pMHC-I levels, T CD8+ death rates, and T CD8+ avidities (by affecting the likelihood of costimulation and, therefore, the probability of activation). Therefore, efforts to incorporate the dynamic impact of inflammation into future models appear warranted.
Third, finding ways to improve the ABC-based methods should enable more reliable estimates of various immune parameters. As is evident from the breadth of the 95% CIs shown in Tables IV through VI, our current estimates vary considerably in their reliability. Specifically, epitope density estimates appear quite reliable, T CD8+ avidity estimates are moderately reliable, and T CD8+ precursor numbers appear much less reliable. There are at least three possible explanations for the latter. First, it could simply be that the summary statistics that we used, the T CD8+ responses at day 7, are not sufficient to properly capture the entire dynamics of the T CD8+ response. However, given the apparent success in using these same parameters to estimate epitope density, this seems unlikely. Second, as one uses ABC to estimate more and more parameters, the accuracy of these estimates may be reduced (42) , but again this did not seem to prevent us from obtaining reliable estimates for epitope density. The third and most likely possibility is that the actual number of T CD8+ precursors does not greatly influence the T CD8+ response (i.e., we obtained a large CI because a wide range of values successfully simulates the observed T CD8+ counts). Nevertheless, looking ahead, it would be interesting to see whether the reliability of our parameter estimates improves if we use additional summary statistics. For example, if we had included a longitudinal component to our initial experimental setup by assessing T CD8+ responses daily from days 5 to 10 postinfection (rather than just day 7), it might be possible that the parameter estimates improve. Similarly, because the performance of the ABC approach also depends upon the fidelity of the model to reallife, future efforts to refine our underlying IBM might also enable improved ABC-based estimates.
In conclusion, we presented a computational modeling approach to better understand the complex dynamics that underlie the generation of primary T CD8+ immune responses. Although this approach has various restriction and caveats, it has nonetheless enabled us to draw useful insights into the basis for understanding how the T CD8+ ID hierarchy is established after influenza infection. Just as importantly, our model also provides a foundation upon which future refinements can be based and will hopefully facilitate the design of in silico methods that can assist in the development of safe and effective vaccines. Table II complexes. All other modeling parameters were set to the default values shown in Table II . 
